We also observed tumor samples with co-occurring driver variants in EGFR, KRAS, and BRAF genes (seven patients with KRAS/EGFR variants; four patients with BRAF/KRAS; one patient with BRAF/EGFR/KRAS). This evidence concerns the gene BRAF and neoplasm.